Perlegen Eyes First-Half '09 Launch of Breast Cancer Dx Panel | GenomeWeb
NEW YORK (GenomeWeb News) – Perlegen Sciences intends to release its first diagnostic product, which is focused on stratifying risk and diagnosing breast cancer, during the first half of 2009, CEO Bryan Walser said on Thursday at the UBS Global Life Sciences Conference here.
 
The panel will contain eight single nucleotide polymorphisms, five of which are exclusive to Perlegen. The firm believes that its panel will have utility in both risk stratification as well as helping to guide treatment selection after diagnosis.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.